ArticleCancer discovery2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel
Open access · greenAbstract readCase Reports
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma.Nature communications · 2025Article
- Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis.Frontiers in oncology · 2023Article
- Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.Molecular biomedicine · 2022Review
- Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer.Theranostics · 2021Article
- Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Isabl Platform, a digital biobank for processing multimodal patient data.BMC bioinformatics · 2020Article
- Discovery through clinical sequencing in oncology.Nature cancer · 2020Review
- Allelic heterogeneity of Proteus syndrome.Cold Spring Harbor molecular case studies · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 5 institutions in 2 countries.
Emily K Slotkin *Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. slotkine@mskcc.org.ORCID 0000-0002-4463-5759
Daniel Diolaiti *Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Neerav N ShuklaDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Filemon S Dela CruzDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jennifer J ClarkRocky Mountain Hospital for Children, Denver, Colorado.
Gunes GundemDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Venkata D YellapantulaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Max F LevineDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Daoqi YouDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Peilin MaDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sagarika PachhalDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Glorymar Ibanez SanchezDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Ryma BenayedDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Achim A JungbluthDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Lillian M SmythDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-0986-9285
Audrey MauguenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Irena GushterovaColumbia University Medical Center, New York, New York.
Hongxu DingColumbia University Medical Center, New York, New York.
Lee SpraggonOxford Genetics, Oxford, United Kingdom.
Robert DarnellNew York Genome Center, New York, New York.ORCID 0000-0002-5134-8088
Andrea CalifanoColumbia University Medical Center, New York, New York.ORCID 0000-0003-4742-3679
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Elli PapaemmanuilDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew L KungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
David M HymanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Stephen S RobertsDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8258-756X
Memorial Sloan Kettering Cancer Center · USColumbia University Irving Medical Center · USInnovative Cryogenic Engineering (United Kingdom) · GBNew York Genome Center · USRocky Mountain Hospital for Children · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MPredicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MSystematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1MHigh-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0MStorage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600kNCI NIH HHS P30 CA008748NCI NIH HHS R35 CA197745NCI NIH HHS U01 CA217858NIH HHS S10 OD012351NIH HHS S10 OD021764NIH HHS U54 OD020355
Abstract
Despite the important role of the PI3K/AKT/mTOR axis in the pathogenesis of cancer, to date there have been few functional oncogenic fusions identified involving the
Indexed as
AnimalsCarcinomaChildDisease ProgressionDrug Resistance, NeoplasmFemaleGene FusionHumansIntracellular Signaling Peptides and ProteinsMiceMice, Inbred NODMice, SCIDMolecular Targeted TherapyPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktAKT1 protein, humanIntracellular Signaling Peptides and ProteinsipatasertibLAMTOR1 protein, humanPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.